Category: Health

Bengaluru (Karnataka) [India], June 22: The easiest way to commercialize anything is by making it generic. That is how assembly-line cars replaced customized horse-drawn carts. And that is how modern medicine works too – the same pill for all diabetics.

But that isn’t how the wellness wisdom of India worked. Ayurveda & Yoga used to be personalized solutions. Just like how all people have varying outward personalities, Indian medicine realized that each person is inwardly unique.

The concept of Prakirti and the classification of people as belonging to the varying combinations of three basic Prakirtis – Vata, Pitta, & Kapha, was the first attempt by ancient medicine, in personalization.

And they survive to this day simply because medicines prescribed based on these prakirtis work like a charm. But generic thoughts invaded these sectors too and Ayurveda & Yoga became commercialized and less effective.

Today, medical research shows that people are unique, based on their genetics & metabolism. Personalized medicine is called precision medicine in the West and has become the buzz.

Vieroots Wellness Solutions, a startup founded by renowned wellness evangelist & biohacker, Dr. Sajeev Nair, specializes in Personalized Lifestyle Management.

Vieroots’ core product EPLIMO analyzes each client’s genetics & metabolism to detect geno-metabolic chances for developing 200 lifestyle diseases and suggests personalized lifestyle modifications spanning diet, supplements, exercise, yoga & meditation, which can keep these diseases at bay.

Recently, Vieroots has taken their yoga-based interventions to a new orbit by tying up with the Himalayan School of Traditional Yoga (HSTY) which is one of the rare yoga schools that practise yoga as Sage Patanjali taught it.

On International Day of Yoga, these two institutions came together to offer the world a glimpse of Personalized Yoga & Meditation. The day started with Vieroots founder, Dr. Sajeev Nair’s virtual Yogathon.

A renowned public speaker and practitioner of yoga & meditation himself, Dr. Sajeev’s session was noted for highlighting the latest research on how Yoga benefits the human body at the cellular & mitochondrial level. Dr. Sajeev also led the audience through a guided meditation on Forgiveness & Gratitude, which proved once again why he is such a life-transforming speaker.

The next session was on ‘Therapeutic Yoga & Meditation for Lifestyle Diseases’ led by Ms. Usha Lakshminarayanan, Head of Studies, and Ms. Subashree Thottungal, both from HSTY. Based on Ms. Usha’s knowledgeable narration, Ms. Subashree displayed several sittings, standing & prone asanas, as well as pranayamas, all of immense therapeutic value.

In the final session, Vieroots presented a dazzling array of yoga theory & practice led by its medical & yoga professionals, Dr. Biju KS, Senior Medical Officer, Dr. Godmi Teresa Sunny, Ayurvedic Doctor & Yoga Practitioner, Ms. Ishara Patrao, Certified Lifestyle Coach & Yoga Instructor; and Vaija Nair, Certified Lifestyle Coach.

ImmunoSEB + ProbioSEB CSC3 for post-resolution of mild to moderate COVID-19 patients

Mumbai, Maharashtra [India], June 21: According to recent stats, 2.77 crores of COVID-19 sufferers were recovered from 2.88 crores cases in India. All corporate offices and businesses want to operate outdoors but worry much about the Post Covid difficulties and resolutions. While companies were involved in launching products and promoting claims that it fights the Coronavirus, researchers ran clinical tests to confirm how consuming immunity supplements resolve mild to moderate COVID-19 patients.

Dr. Neha Shah, Dr. Rohit Parate, and Dr. Abhay Vispute published their findings on a new COVID-19 clinical trial in the Medical Journal of Advances in Clinical Toxicology. A randomized, open-label, 2 Arm, prospective study was investigated for the safety and efficacy of the health supplements. Fortunately, ImmunoSEB + ProbioSEB CSC3 as supplemental therapy was confirmed to be beneficial in mild to moderate COVID-19 patients and showed overall clinical improvement in WHO 7-point ordinal scale.

They investigated to evaluate the effect on the primary endpoint of the experimental regimen through pairwise comparisons of the testing regimen ImmunoSEB + ProbioSEB CSC3 with a standard-of-care control arm and under a sequential design. The clinical trials were carried out on 60 patients in two centers, SRV Hospital, Mumbai and Chirayu Medical College, and Hospital, Bhopal.

As the World Health Organization rightly defines probiotics as “live microorganisms that administer adequate amounts confer a health benefit on the host.” ImmunoSEB + ProbioSEB CSC3 are different as they increase immunity and improves digestion, aiding in reducing fatigue. In addition, it’s a nutraceuticals product, the only product with clinical trials as a supplement to fight against Covid-19.

Recent clinical studies indicate that this Supplement supports the recovery of covid patients. The length of time to experience the benefits of the Supplement varies by individual. Some people notice a difference within days. For others, it’s a week or ten days. For long-term benefits, it’s essential to take the immunity bundle consistently over several months. Regular, consistent use of the Supplement will provide the best results. However, missed doses of the Supplement do not cause any harm. Consume the following amount as per your daily regime.

According to Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series covered by the Medical Journal of Clinical Trials and Case Studies; “The present cases support the use of a 14 days supplementation of a combination of ImmunoSEB + ProbioSEB CSC3 to improve COVID-19 induced fatigue in patients post-resolution of mild to moderate COVID-19 disease. However, there is a need for large-scale, placebo-controlled prospective studies to evaluate this effect further.”

The team of doctors and researchers includes Dr. Neha Shah, Dr. Rohit Parate, Dr. Abhay Vispute.

Dr. Rohit Parate, MD Medicine, Churayu Medical College, and Hospital, observes patients with a Generalised Weakness, Dry Cough, Body Ache, Loss of Appetite, and Constipation for post-covid symptoms. Whereas Dr. Kuldeep Kataria, MD Medicine, Swasthya Hospital, follows over 75% of the patients with Sleep disturbance, Severe Body Ache, Abdominal Cramps, and Heaviness in the chest.

Dr. Sanket Ramesh Mundada, MBBS, DPM, Namrata Neureoschyetric Hospital, Shrirampur conveys, “Post Covid patient with anxiety symptoms, disturbed sleep, depression. Withholding due to the death of the loved ones in Covid, psychosis has increased in OPDs. We have seen cases of fear of getting infected or fear of spreading the infection to family members increasing, causing many palpitations, trembling, sweating in patients. Counseling and appropriate medication help along with immunity booster help maintain the mental and physical health of the patient.”

“Throughout this pandemic situation, we tried hard to fix this unsolvable puzzle of saving lives post-covid with natural solutions that can help people who are grieving. Enzymes and probiotics are robust mechanisms for stamina and vitality, and the medicine and investigation confirm it.” conveys Dr. Neha Shah, Ph.D. Program Coordinator, Navigate a&Swog, VA Long Beach Healthcare, California.

Mr. MukundKabra, Director, Advanced Enzymes, states, “the reason is evident for post-COVID-19 and should heal as any prevalent disease. Advanced Enzymes remedied Americans for over 30 years. Aiding to enhance immunity amongst Indians was our prime focus in this pandemic. Hence, the research-backed Immunity Bundle was made available online. Doctors should address post-COVID immunity immediately because it is affecting a lot of people’s quality of life.”

Dr. Abhijit K Rathi, the Principal Scientist from AET, “ImmunoSEB and Biome Ultra were tested in a few hospitals, clinics, random patients and discovered their feedback. People’s difficulties before the testing were traumatizing. However, after consuming ImmunoSEB and Biome Ultra for some days, the same target group conveyed their curing stories and enhanced immunity evidence.”

Mumbai (Maharashtra) [India], June 17: COVID-19 pandemic revealed the gaps in the existing healthcare structure and showed that the Indian healthcare system is too weak.

With a lower doctor-patient ratio (1:1000), issues in last-mile healthcare delivery, and lack of qualified doctors in rural & semi-urban areas, the Indian HealthCare system needs a revolution.

There is no effective, trusted single window for healthcare delivery to everyone and no proven way for professionals to find, consult, transact with each other online.

Providing a solution to all these issues, JK Singha, Rk Ningthem, Nilesh Bhanushali, and Chittaranjan Mishra started HealWell24.

In Jan 2021, Anil Va Verma, a top executive in a major beauty care startup, joined HealWell24 as Chief Investment Officer.

The idea behind the next chapter of HealWell24 emanates from a deep and personal experience of the team.

It is to solve for the current asymmetry of Indian Healthcare (of information & access), no booking engine (such as HealWell24.com or Practo.com) will ever be sufficient at a scale, which has become obvious to the entire world during the two waves of the Covid-19 pandemic.

It would need a simple engine and a user-managed network of Doctors and Patients, owned and moderated with the community at its center stage.

DocsCampus.com, the upcoming product of HealWell24, plans to solve exactly this in a simple to use and effective platform for the next generation, stated the founder.

The Healthtech startup currently provides an easy-to-use web and mobile platform where members can connect with India’s top doctors – 24/7, 365 days a year.

Speaking about the platform, JK Singha says, “HealWell24, the current product, already empowers individuals with remote screening, where patients can connect with their dedicated doctors anytime, from anywhere, and engage in live video sessions. We also provide additional support, like doctor home visits, home lab tests, or medicine delivery, to our customers- all of which are fulfilled on the same day by our team. But with DocsCampus, we would consider us successful when we have removed the existing asymmetry of access & information for doctors or medical students in rural/ semi-urban areas & their patients.

Although the DocsCampus portal is not expected to be monetized in the coming quarters, till it hits an inflection point, the services of the current booking engine will be deeply integrated to ensure top quality service delivery to all the doctors on the platform and their patients.

The company will be moving into the next phases of DocsCampus lifecycle in the coming three quarters from launch, of which I remain tightlipped but extremely excited about.”

Operational in 35 cities, HealWell24 has 1000+ doctors, 300+ Labs, and 100+ Dentists on its platform. The startup has Apollo Spectra, Indian Oil, Hiranandani Hospital, Mahindra Lifespaces, Synechron technologies, Zeno Health as Corporate Clients, and several well-established companies in diagnostics chains & hospitals as partners.

Till now, HealWell24 has provided essential healthcare service to thousands of Indians for conditions such as bone cancer, dental abscesses, and diabetic retinopathy.

With over 215K consumer transacted so far, HealWell24 currently handles over 600 transactions per day.

HealWell24 has aggressive growth plans and is looking to raise Series A in the next two months. The startup had already raised a total of $1.1Mn from Seed and Its Pre-Series A Rounds.

The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

“Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

“The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

For more information, please visit www.thermofisher.com

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Pune (Maharashtra) [India], June 15: Cancer patients in India now have access to CURIA, a first-of-its-kind app developed by Swiss company OncoCoin AG, the most decentralized and equitable ecosystem of cancer information. CURIA, with a global community of over 150,000, empowers patients with individualised information on treatments, clinical trials, and experts. It provides them with the much-needed support to navigate the tough decisions throughout their treatment journey.

According to a report by WHO, 1 in every 10 Indians will develop cancer in their lifetime. There were as many as 1.16 million new cancer cases and 784,800 cancer deaths in 2018 alone. High mortality, combined with over 500 types of cancers, has generated a need for highly relevant information more than ever before.

CURIA empowers patients and their families with individualized information about approved therapies, clinical trials, and medical experts. Built over the OncoCoin platform, CURIA offers services such as tailored information, second opinion, and the opportunity to participate in research programmes. The timely availability of this information at patient’s fingertips helps them navigate through tough decisions throughout their treatment journey.

Speaking of this, Amit Ananpara, Innoplexus India Co-MD, said “Globally, 70% of cancer patients feel they do not get the information they need to make informed decisions. Specifically in India, limited knowledge of ongoing clinical trials leaves a gap in research involvement, stifling new insights. CURIA has successfully bridged such gaps in Europe. We look forward to helping cancer patients in India in their journey to cure.”

The tailored options in the app seek to answer three main questions which are often at the forefront of patients’ minds when they are diagnosed with cancer: ‘What are the treatment options available to me’, ‘What clinical trials could I participate in’, and ‘Who are the experts for my cancer type’. CURIA serves as a basis for patients to understand those options for their treatment journey, and to have more engaged discussions with their doctors about what’s right for them.

Adding further, Gunjan Bhardwaj, Founder & CEO, Innoplexus, said, “Cancer is one of the most common non-communicable diseases in India today. What exacerbates the situation further is the fact that there is a clear lack of information on the condition. We aim to bridge this gap through CURIA and enable individuals with this condition to connect with other cancer patients and share information.”

CURIA’s popular feature “Cancer Twin”, addresses patients’ need to connect with someone who really understands what they’re going through. The algorithm matches patients with the most similar other cancer profiles. They can share experiences through a private chat, anonymously. All conversations are encrypted through blockchain, bringing in the highest level of security to protect patient’s vital health information.

CURIA’s India launch follows successful launches in Germany, Italy, Spain, Switzerland, and France. It is available on Android and iOS platforms.

About Curia

CURIA is a mobile application developed by OncoCoin AG, a Swiss-based wholly-owned subsidiary of Innoplexus AG. OncoCoin, using its patented AI and blockchain technologies, structures trillions of data points from published and unpublished data. The information is tailored by parameters such as demographics, cancer type, stage, possible mutations, to generate the most relevant insights for quick decision making. The insights are fully regulated by a human team of experts. Curia was founded in June 2020 by Innoplexus AG and sits in Eschborn, Germany. The app is currently available in Germany, India, Italy, France, Spain, and Switzerland.